Satellos Drug Target Review Issue 3 2023
Satellos Drug Target Review Issue 3 2023
SATELLOS to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
TORONTO, September 20, 2023 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB:
SATELLOS Enters into an Agreement with ICP Securities Inc. to Provide Market Marking Services
TORONTO, September 7, 2023 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB:
SATELLOS Expands Leadership Team with New CFO Appointment
Elizabeth Williams, CPA, CA, joins as CFO, bringing extensive expertise leading corporate finance and strategy
SATELLOS Announces Q2 2023 Financial Results and Operational Highlights
$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to
SATELLOS Receives Orphan Drug Designation from the U.S. FDA for SAT-3153, a First-in-Class Small Molecule Therapeutic for Duchenne Muscular Dystrophy
Company also recently received Rare Pediatric Disease Designation from the FDA for SAT-3153 for the
SATELLOS Announces Results From its Annual General Meeting of Shareholders and Adoption of Amendments to Stock Option Plan
TORONTO, June 30, 2023 – Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a
SATELLOS Announces Appointment of Chief Medical Officer
∞ Dr. Alan K. Jacobs joins Satellos as CMO on June 7th, 2023 ∞ TORONTO,
SATELLOS Announces Grant of Stock Options
Satellos Bioscience Announces Grant of Stock Options Toronto, Ontario -- (Newsfile Corp. – June 1,
SATELLOS Announces 2023 Q1 Financial Results and Operational Highlights
SATELLOS BIOSCIENCE ANNOUNCES 2023 Q1 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS - $55 million equity financing